Project Grant R43TR005794
Award Date
7/1/25
Completion Date
6/30/26
Dollars Obligated
$306K
Federal Agency
National Center for Advancing Translational Sciences
Awardee
Simplusdx, Inc. (JHR4MPJF4QW5)
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Eno Valley, NC 27712, USA
Similar Awards
The National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, has awarded a $324,962 Project Grant to Tetmedical, Inc. to develop a technology for rapid, point-of-care and at-home testing of liver enzyme levels. The goal is to enable convenient and timely monitoring of drug-induced liver injury (DILI) and other sources of liver damage. The project aims to optimize tethered enzyme assays for detecting aspartate aminotransferase (AST) and alanine aminotransferase (ALT),...
This $150,000 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) will support the development of a personalized therapeutic drug monitoring (PTDM) system. The objective is to create a smart, home-use system that can provide frequent, noninvasive measurements of drug levels in a patient's saliva and deliver real-time data on circulating...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Electronic Biosciences, Inc. to develop a novel point-of-care technology for monitoring immunosuppressant drug levels. The key product being developed is a portable, fingerstick-based testing system that can provide convenient and frequent immunosuppressant drug level measurements. This will enable more precise dosing for...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $385,250 Project Grant (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) to the University of Florida for a research project titled "Liquid Biopsy Technology Towards Individualized Immunosuppression Therapy". The goal is to use liver-derived extracellular vesicles as biomarkers to predict variability in tacrolimus pharmacokinetics and optimize dosing in liver transplant...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $175,964 to Hepatx Corporation to develop a proteomic assay for monitoring transplanted cells and tissues. The goal is to create a simple blood test that can detect differences in amino acid sequences of donor hepatocyte proteins compared to recipient proteins, enabling the assessment of the success of cell...
This $598,894.00 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of a novel point-of-care rejection and immunosuppression monitoring assay (PRIMA) for vascularized composite allotransplantation (VCA). The primary recipient, Intelligent Optical Systems, Inc., is a manufacturer of optical sensing and instrumentation technologies that specializes in developing innovative medical...
This $249,000 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of a novel split enzyme diagnostic platform for rapid, sensitive detection of protein and small molecule biomarkers at the point of care. The key products and services to be delivered through this grant include: Incorporating binding domains...
This $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the 93.350 CFDA program, supports the development of the Codomax EPI-MAX platform. This integrated omics and computational technology leverages cellular stress responses to enhance the production of difficult-to-express therapeutic proteins, with a focus on improving secretion and preventing aggregation in the Pichia pastoris expression system. The key products or services to be...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $548,830 to Nephsmart LLC to develop and test a point-of-care device that can detect extensive cleavage of a specific protein in the urine, which preliminary data suggests can predict the future development of severe acute kidney injury (AKI). The goal is to create a test that can differentiate between...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...